[ad_1]
WASHINGTON – The modern American pharmaceutical company announced Thursday that it will not file patents for its candidate vaccine against Covid-19 as long as the new coronavirus pandemic persists. The decision, once confirmed, would allow other companies to replicate the immunizing formula, expanding the immunization’s production capacity and facilitating its universalization.
Modern: Company Does Not Complete Enough Black and Latino Volunteers for Vaccine
In a statement, the company said it plans to license intellectual property rights to the product only after the end of the Covid-19 pandemic. The vaccine tested by Moderna is considered one of the main ones in the world race for an immunizer capable of blocking infection by the new coronavirus.
The company received $ 1 billion from Operation Warp Speed, an initiative by the United States government to accelerate the development of potential vaccines against Sars-CoV-2, and another $ 1.5 billion to secure doses for the United States.
Health: The distancing and the use of masks against Covid-19 reverse cases of other respiratory diseases in the country
The vaccine created by the company has a partnership with the US National Institutes of Health (NIH) The formula consists of fragments of RNA, genetic material of the virus. Inside the human body, they would produce proteins from the pathogen capable of stimulating the immune system to attack the coronavirus at the time of infection.
